Ultragenyx Pharmaceutical Inc. (RARE)
| Market Cap | 2.33B -41.7% |
| Revenue (ttm) | 630.60M +20.6% |
| Net Income | -579.83M |
| EPS | -5.94 |
| Shares Out | 96.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,216,269 |
| Open | 23.49 |
| Previous Close | 23.88 |
| Day's Range | 23.49 - 24.68 |
| 52-Week Range | 18.41 - 46.27 |
| Beta | 0.16 |
| Analysts | Strong Buy |
| Price Target | 73.11 (+202.11%) |
| Earnings Date | Feb 12, 2026 |
About RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment... [Read more]
Financial Performance
In 2024, Ultragenyx Pharmaceutical's revenue was $560.23 million, an increase of 29.01% compared to the previous year's $434.25 million. Losses were -$569.18 million, -6.17% less than in 2023.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for RARE stock is "Strong Buy." The 12-month stock price target is $73.11, which is an increase of 202.11% from the latest price.
News
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acqui...
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit
NEW YORK, Feb. 9, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc...
Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)
Data represents up to 8.5 years of follow-up and are consistent across age, dose, and genotype BLA resubmitted to U.S. FDA in January 2026; Company expects up to six-month review period per FDA guidel...
Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
Company expects up to six-month review period per FDA guidelines New longer-term clinical data demonstrating durable positive brain biochemical and clinical effect for as long as 8.5 years to be pres...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar...
Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies
NEW YORK, Jan. 23, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) following the Company's announcement of topline results from its Phase III ...
Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline
Ultragenyx is rated BUY with a $55 price target, offering 145% implied upside after a sharp post-trial selloff. RARE's commercial base, anchored by Crysvita and Dojolvi, provides a robust revenue safe...
Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance Preliminary cash and investments of approximately $735 million as of December 31, 2025 Anticipated 2026 c...
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIa If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIa
Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, Dec. 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ultragenyx Pharmaceutical, Inc. (“Ultragenyx" or the "Company") (NASDAQ: RARE) investors that the firm has initiated an inve...
Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) shares plunged 42% on Monday after the company and partner Mereo BioPharma Group plc (NASDAQ: MREO) disclosed disappointing late-stage data for their rare...
These biotech stocks are getting hammered by shocking brittle-bone treatment study results
Shares of both Ultragenyx and Mereo BioPharma were seeing record selloffs after disappointing trial results for setrusumab.
Ultragenyx's bone disease drug fails late-stage trials
Ultragenyx Pharmaceutical said on Monday that its experimental drug for a type of genetic bone disease did not meet the main goal in late-stage studies.
Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta
Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic)
AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings
Our portfolios underperformed during the quarter and trail year to date. Health care was the primary hindrance as a result of our underweight in biotech and negative stock selection. We have materiall...
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. ( RARE) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Joshua Higa - Director of Investor Relations & Corporate Communications Emil Kakkis - Fo...
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences
Bolsters balance sheet with non-dilutive capital at an attractive cost Beginning in January 2028 OMERS will receive an additional 25% of the North American Crysvita® royalty interest capped at 1.55 ti...
Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update
NOVATO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri...
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice presid...
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Bank of America Global Healthcare Conference 2025 September 23, 2025 6:35 AM EDT Company Participants Eric Crombez - Chief Medical Officer & Executive VP ...
Ultragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:05 PM EDT Company Participants Eric Crombez - Chief Medical Officer & Executiv...
Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
At Week 96 participants experienced even greater reductions in daily cornstarch intake while maintaining low levels of hypoglycemia, improved levels of euglycemia and improved fasting tolerance